1. Home >
  2. M&A >
  3. Spin Off >
  4. United States >
  5. Massachusetts >
  6. Euthymics Bioscience Exits Neurovance

Investment Summary

Euthymics Bioscience Exits Neurovance

On January 1, 2011, invested in life science company Neurovance from Euthymics Bioscience

Investment Highlights
  • This is transaction in the Life Science sector.
  • This is transaction in the United States.
  • This is transaction in Massachusetts.
Investment Fate
  • Neurovance was sold to a strategic buyer in 2017 for 100M USD.

Investment Summary
Date 2011-01-01
Target Neurovance
Sector Life Science
Sellers(s) Euthymics Bioscience
Deal Type Spin Off

Target

Neurovance

Cambridge, Massachusetts, United States
Neurovance, Inc. is a clinical stage neuroscience-focused company. Hypothesis-driven, proprietary research at Neurovance discovered and developed centanafadine (CTN), a triple reuptake inhibitor that represents a novel approach to help adults and children with ADHD, Attention-Deficit Hyperactivity Disorder.

Search 214,877 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Seller(S) 1

SELLER

Euthymics Bioscience

Cambridge, Massachusetts, United States
Category Company
Founded 2009
Sector Life Science
DESCRIPTION

Euthymics Bioscience, Inc. is a developer of novel medicine for alcohol use disorder (AUD) and smoking cessation. The name Euthymics is related to the word "euthymia" which means "mood in the 'normal' range, without manic or depressive symptoms."

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Spin Off M&A Deals 1 of 1
State: Massachusetts M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2011 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal